Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Pfizer, Amgen Seek Companion Diagnostics
by Michael McCoy
January 16, 2012
| A version of this story appeared in
Volume 90, Issue 3
Two cancer diagnostic developers have struck agreements with big pharma companies. Ventana Medical Systems, a Roche company, will work with Pfizer to develop what it calls the first fully automated and standardized immunohistochemistry companion test for ALK gene rearrangements. The test is intended to identify non-small-cell lung cancer patients who may benefit from Pfizer’s recently approved Xalkori. Separately, the Danish firm Dako will develop a diagnostic test for an Amgen cancer drug candidate that targets a rare and deadly cancer.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X